Which has the lower trailing P/E, BVS or RIGL?

RIGL has the lower trailing P/E: BVS trades at 17.01 and RIGL at 2.83. P/E is one valuation measure and does not by itself establish which business is cheaper.

Which has grown faster, BVS or RIGL?

Over the past five years, RIGL grew revenue faster — BVS at a 11.82% CAGR versus RIGL at 13.94%.

Is BVS or RIGL more profitable?

RIGL runs the higher net margin — BVS at 9.36% versus RIGL at 116.30%.

How have BVS and RIGL total returns compared?

Over the past 5 years, BVS delivered -0.81% and RIGL delivered 6.25% annualized total return. Past performance doesn't predict future results.

Bioventus Inc. (BVS) vs Rigel Pharmaceuticals, Inc. (RIGL)

A side-by-side comparison of Bioventus Inc. and Rigel Pharmaceuticals, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.

BVS

Bioventus Inc.

$887M

$13.10HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT

RIGL

Rigel Pharmaceuticals, Inc.

$853M

$46.11HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT

Total return — BVS vs RIGL

growth of $100 · dividends reinvested · last 6y

BVS -29.6% (-5.7%/yr)RIGL +14.6% (+2.3%/yr)RIGL compounded faster over this window

BVS RIGL

BVS vs RIGL: by the numbers

•BVS is the larger company ($887M vs $853M market cap).
•RIGL trades at the lower trailing earnings multiple (2.83 vs 17.01 P/E), one valuation lens rather than an overall verdict.
•RIGL converts more revenue to profit (116.30% vs 9.36% net margin).
•RIGL grew revenue faster over the past five years (13.94% vs 11.82% CAGR).

Metrics side by side

Valuation

Metric	BVS	RIGL
P/E ratio	17.01	2.83
Forward P/E	16.82	13.44
P/S ratio	1.53	3.08
P/B ratio	3.89	2.01
EV / EBITDA	10.48	9.28
FCF yield	10.62%	9.31%

Profitability

Metric	BVS	RIGL
Gross margin	68.00%	91.39%
Operating margin	10.63%	42.63%
Net margin	9.36%	116.30%
ROE	23.86%	75.67%
ROIC	11.37%	18.72%

Growth (annualized)

Metric	BVS	RIGL
Revenue CAGR (5Y)	11.82%	13.94%
EPS CAGR (5Y)	-5.03%	N/A
FCF CAGR (5Y)	43.36%	N/A
Total return CAGR (5Y)	-0.81%	6.25%

Frequently asked

Which has the lower trailing P/E, BVS or RIGL?: RIGL has the lower trailing P/E: BVS trades at 17.01 and RIGL at 2.83. P/E is one valuation measure and does not by itself establish which business is cheaper.
Which has grown faster, BVS or RIGL?: Over the past five years, RIGL grew revenue faster — BVS at a 11.82% CAGR versus RIGL at 13.94%.
Is BVS or RIGL more profitable?: RIGL runs the higher net margin — BVS at 9.36% versus RIGL at 116.30%.
How have BVS and RIGL total returns compared?: Over the past 5 years, BVS delivered -0.81% and RIGL delivered 6.25% annualized total return. Past performance doesn't predict future results.

Go deeper

Full BVS analysis Full RIGL analysis Interactive comparison tool

Dig into the metrics

Bioventus P/E ratio Rigel Pharmaceuticals P/E ratio Bioventus ROE Rigel Pharmaceuticals ROE Bioventus operating margin Rigel Pharmaceuticals operating margin Bioventus revenue growth Rigel Pharmaceuticals revenue growth Bioventus free cash flow Rigel Pharmaceuticals free cash flow

Bioventus & Rigel Pharmaceuticals appear in these rankings

Highest ROE Stocks Highest ROIC Stocks Highest Operating Margin Stocks Highest FCF Yield Stocks

Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.